Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.030
-0.010 (-0.96%)
At close: Jun 29, 2026, 4:00 PM EDT
1.030
0.00 (0.00%)
After-hours: Jun 29, 2026, 5:37 PM EDT
Cardiol Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cardiol Therapeutics stock have an average target of 8.50, with a low estimate of 8.00 and a high estimate of 9.00. The average target predicts an increase of 725.24% from the current stock price of 1.03.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 26, 2026.
Analyst Ratings
The average analyst rating for Cardiol Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $9 | Buy | Maintains | $9 | +773.79% | May 26, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $8 | Buy | Reiterates | $8 | +676.70% | May 18, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
3.32M
EPS This Year
-0.36
from -0.39
EPS Next Year
-0.28
from -0.36
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 10.7M | |
| Avg | n/a | 3.3M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 3,513.4% |
| Avg | - | 993.8% |
| Low | - | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.36 | -0.28 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.